文献速递前列腺癌

中危前列腺癌的主动监测

Active surveillance in intermediate-risk prostate cancer.
PubMed 文献 · BJU Int · 2020-01-16

本文综述中危前列腺癌患者接受主动监测的适应证、前瞻性系列报告的结果,以及分子生物标志物和影像学在筛选合适候选者中的作用。中危患者异质性大,部分惰性病例可从主动监测获益,但传统病理分期不足以充分区分。

要点

  • 中危候选者包括PSA 10–20 ng/mL或Grade Group 2且Gleason 4比例小、MRI阴性或靶向活检阴性者。
  • 组织基因检测有利评分可进一步增加信心。
  • 中危患者异质性大,需临床、基因组和影像生物标志物进行风险分层。

核心结论

  • 主动监测对部分中危前列腺癌患者是有吸引力的选择。
  • 中危患者中既有惰性病程可从主动监测获益者,也有需早期根治性治疗的侵袭性病程者。
  • 传统组织病理分期不能充分捕捉这种异质性。

研究设计与样本

  • 本文为综述,回顾中危前列腺癌人群保守管理的适应证、前瞻性系列报告的结果以及分子生物标志物和影像学的应用。

主要发现

  • 中危候选者为因PSA 10–20 ng/mL或Grade Group 2伴小比例Gleason 4模式而被归为中危,且MRI阴性或感兴趣区靶向活检阴性者。
  • 组织基因检测有利评分可提供进一步保证。
  • 临床、基因组和影像生物标志物是适当风险分层和患者选择的关键。

关键数值与推荐

  • 中危候选者:PSA 10–20 ng/mL或Grade Group 2伴小比例Gleason 4模式,且MRI阴性或靶向活检阴性。
  • 组织基因检测有利评分可进一步保证。

临床怎么用

  • 对精选的中危前列腺癌患者可考虑主动监测。
  • 利用临床、基因组和影像生物标志物进行风险分层以筛选合适患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Active surveillance (AS), now the standard of care for most men with favourable-risk prostate cancer, is appealing for selected men with 'favourable' intermediate-risk prostate cancer. METHODS: This is a review of the indications for conservative management in this population, the outcomes reported in prospective series, and the use of molecular biomarkers and imaging to identify optimal candidates. RESULTS: Candidates are those patients who are categorized as having intermediate-risk disease either because of a prostate-specific antigen level between 10 and 20 ng/mL, or by virtue of having Grade Group 2 disease, with a small percentage of Gleason 4 pattern, and a negative magnetic resonance imaging result or negative targeted biopsy of a region of interest. Confirmation with a favourable score on a tissue-based genetic assay can provide further reassurance. A subset of patients with intermediate-risk disease has indolent disease that may benefit from AS; at the same time, some patients with intermediate-risk disease have an aggressive clinical course that requires early definitive therapy. This heterogeneity is not adequately captured with traditional histopathological staging. Clinical, genomic and radiological biomarkers are the key to appropriate risk stratification and patient selection. CONCLUSIONS: The benefits of AS make it an appealing option for selected patients with intermediate-risk disease.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Klotz L. Active surveillance in intermediate-risk prostate cancer. BJU Int. 2020. PMID: 31647166. doi:10.1111/bju.14935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。